ABIOMED

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abiomed (ABMD) delivered earnings and revenue surprises of 16.09% and 4.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Q2 Earnings and Revenues Surpass Estimates

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q2 FY 2021 revenue of $210 million, up 27% over Q1 FY 2021 and up 2% over Q2 FY 2020 with 29.2% operating margin.

Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands while supporting the heart's pumping function, providing peak flows greater than 3.5 L/min. The first Impella ECP patient was treated by Amir Kaki, MD, an

First Patients Treated with the World's Smallest Heart Pump, the 9Fr Impella ECP

The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results

ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?

DANVERS, Mass.--(BUSINESS WIRE)--The U.S. FDA has granted Abiomed 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™.

FDA Grants 510(k) Clearance for Abiomed's Innovative Cardiopulmonary Support Technology

The stock price of Abiomed, a medical devices company best known for Impella, the world's smallest heart pump, is up roughly 60% since the beginning of this year, significantly outperforming the broader markets, with S&P 500 up a mere 7%. Despite the rally, at the current price of around $270.

Abiomed Is Up 60% This Year, Can The Rally Continue?

New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.

Abiomed's Heart Pump Can Improve Outcomes in Some Patients

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host a virtual meeting to discuss new clinical data presented at TCT Connect.

Abiomed to Host a Virtual Meeting to Discuss New Clinical Data Presented at TCT Connect

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) when Impella is used to achieve a more complete revascularization in a single setting for high-risk percutaneous coronary intervention (PCI) patients. PROTECT III is an ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk P

Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes

Integra LifeSciences Holdings

IART vs. ABMD: Which Stock Is the Better Value Option?

Exelixis

Teladoc

Look for proven resilience and growth prospects on the horizon.

3 Safe Stocks for a Coming Market Crash

Abiomed is definitely not cheap, but there is significant upside left in this stock.

This Medical Device Player Could Be a Top-Notch Pick in 2020

This company's medical products can help patients suffering from COVID-19's most dangerous complications.

This Under-the-Radar Company May Be the Safest Coronavirus Stock to Buy

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed will release financial results for the second quarter of fiscal 2021 on Thursday, October 29, 2020 at 8:00 a.m. ET.

Abiomed Second Quarter Fiscal 2021 Earnings and Conference Call Notification

Some countries, the U.S. in particular, are growing older - i.e. they have "aging populations.

Abiomed: Driven by Demographics and Innovation

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the Raymond James North American Equities Conference.

Abiomed to Hold Fireside Chat at the Raymond James North American Equities Conference

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the 18th annual Morgan Stanley Global Healthcare Conference.

Abiomed to Hold Fireside Chat at the 18th Annual Morgan Stanley Global Healthcare Conference

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

Why Is Abiomed (ABMD) Down 12.4% Since Last Earnings Report?

DexCom

IDEXX Laboratories

Regeneron Pharmaceuticals

West Pharmaceutical Services

Some of the names on this list may surprise you.

These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020

Bio-Rad Laboratories

Danaher

Hologic

Thermo Fisher Scientific

Vertex Pharmaceuticals

Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.

These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020

Carrier Global

Cadence Design Systems

Coty

Delta Air Lines

Diamondback Energy

PayPal

Royal Caribbean Cruises

Tractor Supply

Wells Fargo

19 S&P 500 stocks are up more than 50% year to date through Aug. 19. A total of 24 are down 50%.

10 S&P 500 Stocks to Buy for Growth and Value

ABIOMED, Inc. (ABMD) CEO Michael Minogue on Q1 2021 Results - Earnings Call Transcript

ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1

Abiomed (ABMD) delivered earnings and revenue surprises of 176.19% and 19.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Tops Q1 Earnings and Revenue Estimates

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q1 FY 2021 revenue of $165 million and 21% operating margin.

News for ABIOMED Stock (ABMD)